MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2022

The clinical development of fostrox remains our focus  April – June Financial summary for the quarter · Net turnover amounted to SEK 0.5 (0.9) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -21.5 (-17.1) million. Basic and diluted earnings per share amounted to SEK -0.42 (-0.31) and SEK -0.42 (-0.31) respectively. · Cash flow from operating activities amounted to SEK -17.6 (-21.9) million. · Cash and cash equivalents at the end of the period amounted to SEK 162.8 (247.8) million.   Significant events during the